IPC 2024 Preview
Raclac offers high quality gloves that ensure safety with precision. Menarini, Abbott, and B Braun present a variety of healthcare solutions, from innovative devices to advanced hygiene technology. Furthermore, Molnlycke with their wound care expertise and PDI International with infection control solutions, contribute significantly to the conference’s thematic areas. The collaboration between the IPC conference and many other sponsors reflects a symbiont effort to advance healthcare practices, creating an environment where knowledge exchange and cutting-edge products converge for the betterment of the healthcare sector.
A must-attend IPC event The IPC Conference 2024 is not just an event; it’s a journey towards a safer tomorrow. By fostering knowledge exchange, collaboration, and hands-on learning, the conference aims to empower healthcare professionals with the knowledge and tools needed to excel in infection prevention and control. Experts will share new ways to keep patients safe from infections, offering delegates the opportunity to learn about the latest strategies to fight germs and ensure antibiotics work when we need them. To register, visit: https://www.
infectionpreventioncontrol.net/tickets/
Exhibition The latest innovations and solutions to help protect patients from healthcare-associated infection will also be showcased at the event. Exhibitors highlighting their expertise, technologies, solutions and services include:
New antimicrobial full body wash Mölnlycke Health Care UK has introduced a new pharmaceutical antiseptic full body wash, Hibiwash, which bonds to and cares for the skin while killing microorganisms. Hibiwash helps prevent infections, promotes skin’s integrity and saves time before performing surgical procedures. With 4% Chlorhexidine Gluconate and emollients, the wash contains the same active ingredients as Hibiscrub. With no colour, no fragrance, and no traces of soya
oil, it is less likely to create skin irritation or an allergic reaction. It also offers the potential for increased compliance, a more sustainable product, using fewer raw materials, as well as using less energy in its production. Visit stand B4 to discuss education packages combined with Hibiwash.
Vira-Protect is formulated using a blend of silver ions and water-based paint compatible polyurethane, creating a hardwearing and efficient paint that supports infection control. The paint is certified to reduce bacteria by 99.9% in 24 hours including Staphylococcus aureus and human coronavirus. This certification ensures the efficacy of Vira-Protect in combating harmful pathogens.
Reducing the risk of transmission of pathogens Seal Shield, a leader in infection prevention technology, and The Keyboard Company (UK), have many years of experience supplying infection control products to healthcare professionals worldwide. Seal Shield pioneered the first washable keyboard and mouse in 2006 and soon established a market-leading position in the US. That same year, a partnership with The Keyboard Company was established to enhance service excellence and product availability within the UK health sector. Seal Shield’s mission is the commitment
to reducing cross-contamination across all industries through innovative solutions. From their state-of-the-art waterproof keyboards to the ElectroClave UV-C Sanitisation System, facilities can be confident that all their mobile devices and IT equipment are covered.
Protective paint reduces bacteria Committed to quality, Protection Paints manufactures paints to meet ISO9001 standards, ensuring consistency and reliability in each batch. The company recognises the critical need for effective solutions to combat the spread of harmful bacteria and viruses, particularly in high traffic areas such as medical facilities, educational institutions and hospitality venues. The company has introduced Vira-Protect, an
innovative dual-action paint designed to provide superior protection against viruses and bacteria. Leveraging nearly 40 years of expertise in protective coatings, Vira-Protect uses cutting- edge technology to create a safe and hygienic environment for all.
32
www.clinicalservicesjournal.com I April 2024
Preventing UTIs Aspire Pharma’s iAluRil is a class III medical device used to treat and manage a range of bladder conditions. iAluRil is proven clinically superior to low-dose antibiotic prophylaxis in the long-term prevention of recurrent urinary tract infections (UTIs) and is also used to effectively treat bladder pain syndrome and interstitial cystitis. Presented in a pre-filled syringe, its unique combination of high dose hyaluronic acid, chondroitin sulphate and calcium chloride effectively replenish the glycosaminoglycan (GAG) layer, establishing an impermeable bladder surface.
Application of genomics for effective outcomes Eurobioscientific UK is the UK based arm of Eurobioscientific, a French manufacturer and distributor of diagnostic assays and equipment within the areas of oncology, transplant, infectious disease and immunity. Vela is distributed by Eurobioscientific across Europe with technicians and business managers based at the UK site in Dorking. Vela Diagnostics provides an integrated sample-to-result NGS system, featuring automated library preparation for efficient and reproducible sequencing. Their ready-to-use panels target clinically significant pathogens like HIV-1, HCV, and oncological markers, emphasising precision healthcare. Each meticulously designed test adheres to rigorous regulatory and research lab standards, ensuring reliable, high-quality genomic data. This commitment supports personalised medicine, aiming to tailor
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
